Esperion Therapeutics Inc (ESPR)

Dec 21, 2024

Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 21, 2024

Dec 20, 2024

ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Dec 20, 2024

Dec 20, 2024

Wellington Management Group LLP Acquires 241,512 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 20, 2024

Dec 19, 2024

Analysts Offer Predictions for ESPR FY2024 Earnings - MarketBeat

Dec 19, 2024

Dec 19, 2024

Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock By Investing.com - Investing.com Canada

Dec 19, 2024

Dec 18, 2024

Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock - Investing.com India

Dec 18, 2024

Dec 18, 2024

Cantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - MSN

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics issues $100M in new convertible notes - Investing.com

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics issues $100M in new convertible notes By Investing.com - Investing.com UK

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 18, 2024

Dec 18, 2024

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at The Goldman Sachs Group - MarketBeat

Dec 18, 2024

Dec 18, 2024

Esperion secures $150 million loan and $100 million notes By Investing.com - Investing.com UK

Dec 18, 2024

Dec 18, 2024

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewswire

Dec 18, 2024

Dec 18, 2024

Esperion Secures $250M in Strategic Financing, Restructures 80% of Debt in Major Deal - StockTitan

Dec 18, 2024

Dec 17, 2024

Cantor Fitzgerald starts coverage on Esperion stock, highlights strong potential for NEXLETOL - Investing.com Canada

Dec 17, 2024

Dec 17, 2024

Cantor Fitzgerald Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat

Dec 17, 2024

Dec 17, 2024

Esperion announces $210M convertible debt financing - MSN

Dec 17, 2024

Dec 17, 2024

Esperion Therapeutics, Inc. announced that it expects to receive $42.5 million in funding - Marketscreener.com

Dec 17, 2024

Dec 15, 2024

Future of Heterozygous Familial Hypercholesterolemia Drug - openPR

Dec 15, 2024

Dec 14, 2024

Esperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Dec 14, 2024

Dec 13, 2024

Esperion Announces $210 Million Convertible Debt Financing - GlobeNewswire

Dec 13, 2024

Dec 13, 2024

Esperion Secures $210M Debt Restructuring Deal with Strategic Convertible Notes Offering - StockTitan

Dec 13, 2024

Dec 13, 2024

Esperion secures licensing deal for heart drugs in Israel By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

Esperion Partners with Neopharm to Commercialize NEXLETOL® - GlobeNewswire

Dec 12, 2024

Dec 12, 2024

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET - The Bakersfield Californian

Dec 12, 2024

Dec 12, 2024

Esperion Therapeutics Expands Global Reach with New Israeli Licensing Deal for Cholesterol Drugs - StockTitan

Dec 12, 2024

Dec 10, 2024

Esperion stock soars to 52-week high, hits $3.81 By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 09, 2024

Esperion stock soars to 52-week high, hits $3.81 - Investing.com

Dec 09, 2024

Dec 08, 2024

Will The Long Awaited Breakout For Esperion Therapeutics Hold? (NASDAQ:ESPR) - Seeking Alpha

Dec 08, 2024

Dec 08, 2024

Anson Funds Management LP Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 08, 2024

Dec 07, 2024

Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpTime to Buy? - MarketBeat

Dec 07, 2024

Dec 06, 2024

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada - MSN

Dec 06, 2024

Dec 04, 2024

Parkman Healthcare Partners LLC Cuts Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 04, 2024

Dec 03, 2024

Approval Sought in Japan for New Drug to Lower Cholesterol - Streetwise Reports

Dec 03, 2024

Dec 03, 2024

Esperion stock soars to 52-week high of $3.41 amid robust gains - Investing.com Nigeria

Dec 03, 2024

Dec 02, 2024

Esperion seeks Health Canada approval for cholesterol drugs - Investing.com Canada

Dec 02, 2024

Dec 02, 2024

Esperion stock soars to 52-week high of $3.41 amid robust gains By Investing.com - Investing.com South Africa

Dec 02, 2024

Dec 02, 2024

Esperion seeks Health Canada approval for cholesterol drugs By Investing.com - Investing.com UK

Dec 02, 2024

Dec 02, 2024

Esperion Announces New Drug Submissions in Canada for - GlobeNewswire

Dec 02, 2024

Dec 02, 2024

Esperion Seeks Canadian Approval for Two Novel Cholesterol-Lowering Drugs | ESPR Stock News - StockTitan

Dec 02, 2024

Dec 02, 2024

FY2025 EPS Estimate for Esperion Therapeutics Cut by Analyst - MarketBeat

Dec 02, 2024

Dec 01, 2024

Wasatch Advisors LP Purchases 6,483,070 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 01, 2024

Nov 30, 2024

Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7%What's Next? - MarketBeat

Nov 30, 2024

Nov 28, 2024

Connor Clark & Lunn Investment Management Ltd. Buys 295,378 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Nov 28, 2024

Nov 27, 2024

Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 27, 2024

Nov 26, 2024

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire

Nov 26, 2024

Nov 21, 2024

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 21, 2024

Nov 21, 2024

Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan

Nov 21, 2024

Nov 21, 2024

Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Esperion's chief commercial officer sells shares worth $426 - Investing.com

Nov 20, 2024